New drugs and imported drugs actually differ somewhat in their definitions. Imported drugs basically refer to drugs originally developed and produced abroad, while new drugs basically refer to drugs that have not yet been widely used or popularized in the clinic after they have been developed, developed and approved for marketing in clinical trials and research. However, due to the gap between domestic and foreign strength in the development of western drugs (especially antitumor drugs), the new drugs developed are basically imported drugs, so it can be said that most of the new drugs are imported drugs. At present, in the field of malignant tumor treatment, there has not yet appeared a certain drug can cure the tumor or achieve better clinical efficacy than other drugs, and for any kind of malignant tumor there is a drug-resistant this thorny problem, so malignant tumor patients and their families are often unanimous in the eyes of the new drugs, and reported great hope, the results are often disappointing. Therefore, here we get to know the new drugs together, and see under what circumstances we should choose the new drugs instead of just chasing after the new ones. First of all, let’s take a look at the difference between new drugs and other drugs. The basic definition of a new drug is a drug whose chemical structure, drug components and pharmacological effects are different from those of existing drugs. It is better understood according to its literal meaning, which is both newly developed and developed drugs. In layman’s terms, every new drug has undergone rigorous experimental research and animal studies prior to its development, confirming that it is safe, that its therapeutic effect on human beings is significantly better than its adverse effects, and that the adverse effects can be controlled, before it can enter the stage of clinical research by means of ethical argumentation, and its safety and efficacy are further confirmed during the stage of clinical research, so that it can be approved and marketed precisely. Although it has undergone a long period of experimental and clinical research before being listed on the market, and its safety and efficacy have been initially confirmed, its long-term adverse reactions and safety are still unknown compared to the commonly used drugs that have already been popularized by the application of the drug. For example, the history of the famous “seal child” event: in 1961 in the former West Germany obstetricians and gynecologists in an academic conference, three physicians reported that thousands of newborns were found to occur deformities (no arms and legs, hands and feet directly on the torso, looks like a seal, known as the “seal limb deformities “After research, it was found that the culprit of this incident was a drug called “Reaction Stop”, which was first synthesized in Germany in 1953, and was very effective in treating nausea and vomiting in the early stages of pregnancy, however, its serious long-term adverse effects were not discovered until nearly 10 years later. Here, we are not saying that a new drug needs to be observed for 10 years to prove its safety, but we are trying to show that the long-term safety problems of a new drug may not have been discovered due to time, and 10 years may not be enough! In contrast, drugs that are already in widespread use have a significantly better understanding of immediate and long-term safety than new drugs, although it cannot be said that all of their safety issues have been 100% clarified. And, although the new drugs have adopted a new pathway of pharmacological action, but not a panacea, not all patients can play the expected efficacy, not blindly chasing the new and have high expectations, may end up because of the disappointment of the blow and exacerbate the deterioration of the disease, the loss is not worth the gain. New drugs still have their specific advantages, which is why we need to choose new drugs, and under what circumstances the choice of new drugs. A new drug is defined as a drug that is different from other drugs in terms of its chemical structure, pharmacological composition and pharmacological effects, that is to say, it is based on new or unapplied physiological, pathological and pharmacological theories, and is different from other drugs in terms of its essential effects. Therefore, it may achieve better clinical efficacy than other drugs, or be combined with other drugs to achieve more clinical efficacy, or to deal with diseases where other drugs are ineffective. When should we consider choosing a new drug? The field of malignant tumor therapy is rapidly evolving, with new discoveries and ideas emerging almost daily, yet there are still some tumors that do not respond significantly to antitumor therapy. For example, pancreatic cancer, known as the king of cancers, has a short survival period and high mortality rate, its treatment has been significantly improved after the application of gemcitabine, but after that it has entered a period of plateau, and the research done at present is basically a combination treatment of mule plus other drugs, although some efficacy has been achieved in some patients, the toxic side-effects are very serious and it is unsuitable for popularization of its application. For these patients, choosing a new drug for treatment or entering a new drug study after gemcitabine treatment progresses is better than sitting on the sidelines, even though it is only a possibility to achieve further clinical efficacy. Tumor drug resistance is currently the most difficult problem for clinicians, and is also the largest behind the scenes of progressive disease progression in tumor patients, even in chemo-sensitive pathology type of tumor patients, at most after 8-12 cycles of chemotherapy will often appear drug resistance, and the most headache is multi-drug resistance. At this time, as the new drug is developed on the basis of new physiopathological foundation and pharmacological action, there is a certain possibility that it will not be affected by the previous drug treatment and multidrug resistance, which gives the doctors a new weapon and brings back a sunny sky. Finally, there is another issue that one has to consider: the economy. In terms of China’s current medical system and the degree of medical insurance coverage, new drugs basically can not be reimbursed by medical insurance, and new drugs are basically imported drugs, expensive, often a month of treatment costs in the tens of thousands of dollars, for the average family is a heavy burden. In short, the new drug is not a panacea, in the right time, under the right circumstances to choose a new drug for treatment, rather than blindly chasing after the new, perhaps also can be called a kind of art of choice. Have you mastered it?